Platysmal Bands: Comprehensive Clinical Evaluation and Botulinum Toxin Treatment Strategies

Introduction and Clinical Significance

Platysmal bands represent one of the most visible and aesthetically concerning manifestations of facial and cervical aging. These prominent vertical bands running along the ventrolateral neck result from progressive laxity and diastasis of the platysma muscle, occurring in the majority of individuals by the fifth and sixth decades of life. While the condition is fundamentally a structural change in muscular architecture, modern nonsurgical treatment using botulinum toxin has emerged as an effective first-line intervention capable of producing significant clinical improvement in appropriately selected patients. Understanding the anatomic basis of band formation, the biomechanics of treatment, and the technical details required for optimal outcomes is essential for dermatologists and aesthetic practitioners managing neck rejuvenation.

Anatomy of the Platysma and Related Structures

The platysma is a broad, thin, superficial muscle covering the anterior and lateral neck. Unlike most muscles of the body that lie within deep fascial planes, the platysma is unique in its location within the subcutaneous tissue, positioned between the skin and the superficial cervical fascia. Embryologically derived from the second branchial arch, the platysma originates from the fascia covering the deltoid and pectoralis major muscles in the upper thorax and inserts onto the mandibular border, lower facial muscles, and the skin of the lower face.

Innervation is segmental, derived from the cervical plexus and cervical branches of the facial nerve (cranial nerve VII). Motor innervation demonstrates distinct regional variation: the upper two-thirds of the platysma receives motor end-plates clustered in the suprahyoid region, while the lower third is predominantly sensory territory. This anatomic distinction has important implications for injection strategy and the risk of complications from toxin diffusion.

Critical to understanding neck anatomy is the relationship between the platysma and the superficial musculoaponeurotic system (SMAS). These structures are anatomically inseparable; the superficial cervical fascia envelops the platysma and blends seamlessly with the SMAS in the face. Contemporary anatomic nomenclature increasingly refers to this combined structure as the SMAS-platysma complex (SMASP), reflecting the functional unity of these layers. The implication is that treatment of the platysma affects and may be affected by changes in the SMAS above the mandibular border.

Pathophysiology of Platysmal Band Formation

Platysmal bands develop through multiple, often simultaneous pathophysiologic mechanisms. The primary theory involves progressive loss of muscular tone combined with medial diastasis of the paired platysma muscles. As individuals age, decreased muscle tone allows the medial borders of the left and right platysma to separate, creating the characteristic vertical bands visible on the ventral neck. The bands represent the medial edges of each platysma muscle, visible as they separate from the midline.

Secondary contributory factors include skin laxity from loss of dermal elastin and collagen, decreased subcutaneous fat volume in some patients, and gravitational descent of the SMAS-platysma complex. An alternative but less universally accepted theory suggests that platysmal bands may result from increased muscle activity rather than loss of tone; proponents of this mechanism argue that chronic platysmal contraction during speaking, swallowing, and emotional expression may lead to progressive shortening and prominence of the muscle fibers.

Anatomic variation significantly influences the severity and appearance of bands. Individuals with longer, more robust platysma muscles demonstrate more prominent bands, while those with shorter or thinner muscles may show minimal banding even with significant loss of tone. Gender differences also exist; women frequently develop more subtle bands, while men tend to demonstrate more prominent vertical banding. Age-related changes in skin quality, particularly increased skin laxity and decreased dermal thickness, amplify the visual prominence of underlying muscular diastasis.

Clinical Presentation and Assessment

Platysmal bands are typically vertical linear prominences visible in the ventral and ventrolateral neck, most apparent when patients smile, speak, or tense the neck musculature. On physical examination, patients should be instructed to turn their head to one side, raise their chin, and expose their lower teeth; this maneuver contracts the platysma and makes bands maximally visible and palpable. Assessment should evaluate both the medial (midline) bands and lateral bands, which may respond differently to treatment.

The vertical dimension of band involvement varies: some bands extend the full length of the neck, while others involve only the superior or inferior portions. The degree of skin laxity should be independently evaluated, as significant skin redundancy may necessitate surgical intervention rather than neurotoxin injection alone. Patients with severe skin laxity, significant subcutaneous fat loss, or extensive jowling typically require more comprehensive treatment strategies including consideration of surgical platysmaplasty.

Botulinum Toxin Mechanism and Clinical Rationale

Botulinum toxin (BoNT), primarily onabotulinumtoxinA and abobotulinumtoxinA, achieves clinical benefit in platysmal banding through selective chemical denervation of the platysma muscle fibers. The toxin blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, preventing muscle contraction. By weakening the platysma, the toxin reduces the visible prominence of the bands and may provide secondary benefit through lifting effects on the mandibular border and jawline.

The clinical benefit in platysmal bands occurs through two mechanisms: direct reduction in platysmal muscle prominence and contractility, and indirect effects on the depressor structures of the lower face and neck. The platysma acts as a depressor of the mandible and lower face; weakening this muscle reduces its downward pull, allowing the natural elevator muscles of the face to create relative lifting of the jawline and softening of the mentolabial angles. This secondary effect, termed botulinum rebalancing, forms the basis for the Nefertiti lift technique, which combines platysmal injection with injections along the mandibular border to create jawline lifting and neck rejuvenation.

Injection Technique and Anatomic Approach

Precise injection technique is essential for optimizing results while minimizing complications. The standard approach for platysmal band treatment involves identification and direct injection into each prominent band, typically conducted with the patient in supine or semi-recumbent position to allow adequate visualization of neck anatomy.

Patient Positioning and Preparation: Patients should be instructed to turn their head to the contralateral side, raise their chin, and contract the platysma by exposing lower teeth or pulling the corners of the mouth downward. This maneuver maximally tenses the bands, making them clearly visible and palpable. The provider should outline the bands with a skin-marking pen, identifying both medial (midline) and lateral band locations.

Injection Sites and Spacing: Using a 30-gauge needle, inject approximately 2 to 4 units of onabotulinumtoxinA (or equivalent doses of alternative BoNT formulations) per injection site. Space individual injection sites 1.0 to 2.0 centimeters apart along the length of each band, concentrating injections in the upper two-thirds of the platysma where motor end-plates are most densely distributed. Typical treatment involves 8 to 12 injection sites per band (per side), producing a total dose of 30 to 50 units for bilateral treatment of medial and lateral bands.

Depth of Injection: Inject at the superficial subdermal level (approximately 2 to 3 millimeters depth) to target the platysma fibers. The thin architecture of the platysma requires careful attention to depth; injections too deep risk affecting underlying structures, while superficial injections may not adequately penetrate the muscle layer.

Alternative Ultrasound-Guided Approach: Advanced practitioners may employ ultrasound guidance to visualize the platysma and ensure accurate needle placement. Ultrasound-guided techniques allow delivery of 30 to 60 units of botulinum toxin per side at 15 injection sites concentrated in the upper two-thirds of the platysma and along the marginal mandibular border, with precise visualization of needle depth and proximity to critical structures including the mandibular branch of the facial nerve and submandibular gland.

The Nefertiti Lift Technique

The Nefertiti lift represents an integrated approach combining platysmal band treatment with targeted injections along the inferior mandibular border to achieve comprehensive neck and jawline rejuvenation. This technique, first described in the dermatologic literature in the mid-2000s, leverages the rebalancing principle to lift and contour the jawline while simultaneously addressing vertical neck banding.

Treatment Components: The Nefertiti lift involves two primary injection zones: the platysmal bands (as described above) and a line of injections along the mandibular border and inferior jawline. Along the mandibular border, inject 2 to 4 units of botulinum toxin at injection points spaced approximately 1 centimeter apart, creating a continuous line of treatment along the inferior border of the mandible from the jowl area posteriorly to the midline anteriorly.

Mechanism of Jawline Lifting: The platysma acts as a powerful depressor of the mandible and lower face. Weakening the platysma through toxin injection reduces this downward mechanical force, allowing the natural elevator muscles of the face (particularly the masseter and anterior belly of the digastric muscle) to produce relative lifting of the chin and jawline. The mandibular border injections target any residual depressor activity at the marginal mandibular nerve branches, further enhancing the lifting effect.

Typical Nefertiti Dosing: A comprehensive Nefertiti lift typically requires 40 to 60 units of onabotulinumtoxinA per treatment session, distributed across platysmal bands (30 to 40 units total) and mandibular border injections (10 to 20 units), with some variation based on individual anatomy and muscle mass.

Dosing Guidelines and Maximal Safety Limits

Appropriate dosing is critical for balancing therapeutic benefit against the risk of complications from toxin diffusion. The literature provides clear guidance on safe and effective dosing ranges.

Standard Dosing for Platysmal Bands: The consensus recommendation from multiple dermatologic and aesthetic societies suggests dosing of 30 to 50 units of onabotulinumtoxinA per treatment session for bilateral platysmal band treatment. Studies demonstrating efficacy and safety have consistently employed doses within this range.

Maximal Dosing Considerations: A French multidisciplinary consensus has recommended a maximal total dose of 100 units of onabotulinumtoxinA for platysmal band treatment, even in cases of severe banding. Most experienced practitioners employ no more than 30 to 60 units per treatment session. The rationale for this conservative approach relates to the documented risk of serious complications including dysphagia, dysphonia, and neck weakness with excessive doses.

Per-Injection-Site Dosing: Individual injection sites should receive 2 to 4 units of onabotulinumtoxinA. Limiting individual injection volumes to 0.025 to 0.05 milliliters (when diluting at standard concentrations) ensures superficial intradermal deposition and reduces the risk of toxin diffusion into deeper structures.

Complications and Risk Mitigation

While botulinum toxin injection for platysmal bands is generally safe, several significant complications have been documented in the literature, particularly with excessive dosing or improper injection technique.

Dysphagia (Difficulty Swallowing): This represents the most concerning complication, occurring when toxin diffuses into the pharyngeal and esophageal muscles responsible for deglutition. Published case reports document dysphagia following platysmal injection, including one severe case requiring nasogastric tube feeding for six weeks after injection of only 60 units of onabotulinumtoxinA. Dysphagia risk increases markedly with doses exceeding 75 units and with injection techniques that penetrate deep into the muscle or place toxin in close proximity to the larynx. Risk mitigation includes: limiting total dose to 50 units or less, concentrating injections in the upper two-thirds of the platysma, maintaining superficial injection depth, and avoiding injections directly into the sternocleidomastoid muscle.

Dysphonia and Voice Changes: Hoarseness, breathiness, and high-tone disturbances in voice quality may occur 3 to 4 days after injection, particularly with doses exceeding 75 units. The mechanism involves toxin diffusion into the laryngeal muscles and vagus nerve territories. Most cases resolve spontaneously within 2 to 4 weeks as toxin effect wanes.

Neck Weakness and Floppy Neck: Excessive dosing or deep injection may result in generalized neck weakness, difficulty holding the head upright, or the sensation of a "floppy neck." This complication reflects broader toxin diffusion affecting multiple cervical muscles. Risk mitigation emphasizes conservative dosing and proper injection depth.

Xerostomia: Reduced salivary flow may occur with toxin diffusion into the submandibular gland, which lies in close anatomic proximity to the injection sites. This complication is usually mild and self-limited.

Standard Injection Complications: Like all injectable procedures, localized swelling, bruising, redness, and temporary discomfort may occur. Infection is rare but possible with any percutaneous injection; maintaining strict aseptic technique is essential.

Duration of Effect and Retreatment Intervals

Botulinum toxin effects on platysmal bands develop gradually over 3 to 7 days, with maximal effect achieved by 2 weeks. Results typically persist for 4 to 6 months, after which platysmal muscle function gradually returns and bands may re-emerge. Retreatment every 4 to 6 months is typically required to maintain results, with some patients observing longer duration (6 to 9 months) and others requiring more frequent treatment (every 3 to 4 months).

With repeated treatments, some patients report that platysmal function remains somewhat diminished even before scheduled retreatment, potentially allowing for longer intervals between treatments. Conversely, high-metabolism individuals may require more frequent retreatment schedules.

Combination and Complementary Treatment Approaches

Optimal neck rejuvenation frequently requires combination of multiple modalities rather than neurotoxin injection in isolation. Consideration should be given to concurrent or sequential treatment with:

Dermal Fillers: Hyaluronic acid fillers or other soft tissue fillers can address volume loss in the neck and jawline areas, providing contouring and structural support that complements the lifting effects of botulinum toxin. Fillers are particularly valuable in patients with significant skin laxity or volume loss.

Energy-Based Devices: Radiofrequency (RF), ultrasound (microfocused ultrasound with visualization, or MFU-V), and laser devices can provide skin tightening through collagen remodeling, addressing both skin laxity and improving the appearance of bands by improving overall skin quality and contraction. These modalities are often combined with neurotoxin injection for comprehensive results.

Topical Treatments: Retinoid-based products and other evidence-based skincare can improve skin texture and thickness in the neck region, providing adjunctive benefit to injectable treatments.

Surgical Platysmaplasty: Patients with severe platysmal banding, significant skin laxity, or poor response to neurotoxin injection may be candidates for surgical platysmaplasty, which involves surgical plication or approximation of the separated platysma muscles and often includes excision of redundant skin. Surgical intervention provides more durable results (5 to 10 years or longer) but involves longer recovery and inherent surgical risks.

Patient Selection and Expectations

Optimal patient selection is essential for satisfaction and appropriate outcomes. Ideal candidates for botulinum toxin treatment of platysmal bands are:

• Patients with mild to moderate platysmal banding and minimal skin laxity
• Patients seeking nonsurgical treatment options
• Patients with realistic expectations regarding the degree of improvement achievable through neurotoxin injection alone
• Patients who understand the temporary nature of results and are willing to commit to maintenance treatments

Patients with severe skin redundancy, significant volume loss, extensive jowling, or very severe platysmal diastasis may require surgical intervention or combination approaches including fillers and energy-based devices for optimal outcomes. Detailed consultation and patient education regarding realistic results are essential before treatment.

References

• Anatomy, Head and Neck, Platysma. StatPearls. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/NBK545294/
• Optimizing Botulinum Toxin Injections in the Platysma Muscle Based on Motor Nerve Distribution. Journal of Cosmetic Dermatology. 2025; 24:e70301. https://onlinelibrary.wiley.com/doi/10.1111/jocd.70301
• Anatomical Proposal for Botulinum Neurotoxin Injection Targeting the Platysma Muscle for Treating Platysmal Band and Jawline Lifting: A Review. Toxins. 2022; 11(12):723. PMC9783622.
• Botulinum Toxin-A Chemical Denervation for Platysmal Bands: Maximal Dosing Considerations. Journal of Drugs in Dermatology. 2015. https://pubmed.ncbi.nlm.nih.gov/26355609/
• Mild to Moderate Dysphagia Following Very Low-dose Abobotulinumtoxin A for Platysmal Bands. Journal of Drugs in Dermatology. 2017. https://jddonline.com/articles/mild-to-moderate-dysphagia-following-very-low-dose-abobotulinumtoxin-a-for-platysmal-bands
• Platysma Prominence: Review and Expert Analysis of Clinical Presentation, Burden, and Treatment Considerations. Aesthetic Surgery Journal. 2024. PMC11798379.
• The Functional Anatomy and Innervation of the Platysma is Segmental: Implications for Lower Lip Dysfunction, Recurrent Platysmal Bands, and Surgical Rejuvenation. Plastic and Reconstructive Surgery. 2024. PMC10702465.
• Botulinum Toxin Treatment for Mild to Moderate Platysma Bands: A Systematic Review of Efficacy, Safety, and Injection Technique. Dermatologic Surgery. 2018. https://pubmed.ncbi.nlm.nih.gov/30052764/